OncoMed Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OncoMed Pharmaceuticals, Inc. - overview
Established
2004
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
OncoMed Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The company utilizes cutting-edge research to advance its portfolio of monoclonal antibodies and cancer stem cell therapies. OncoMed Pharmaceuticals, Inc.
was founded in 2004 in Redwood City, US, focusing on drug development for oncology. The company underwent a significant funding event in July 2013, raising USD 82 million in its IPO by selling 4. 8 million shares at USD 17 per share. OncoMed has completed a total of 10 deals to date.
OncoMed Pharmaceuticals specializes in creating monoclonal antibodies aimed at targeting cancer stem cells. Their product offerings include investigational therapies designed to disrupt cancer cell proliferation and survival, which are intended to improve treatment outcomes for patients with various types of cancer. In 2018, OncoMed Pharmaceuticals reported a revenue of USD 44. 42 mn, with an EBITDA of USD -8.
35 mn, indicating a loss during that year. OncoMed Pharmaceuticals plans to utilize its most recent funding from July 2013 to enhance research and development efforts for new oncology products. The company aims to expand its market presence in North America and Europe, targeting specific cancer indications by 2025. Ongoing collaborations are expected to facilitate the commercialization of promising therapies as they progress through clinical trials.
Current Investors
Latterell Venture Partners, Morgenthaler Ventures, US Venture Partners
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Oncology/Cancer Treatment
Website
www.oncomed.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.